Conditions: Hypertension
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 28
Healthy volunteers: yes

Brief summary:
This study will be an open-label, randomized, two-treatment, two-period, two-sequence crossover study to evaluate the bioequivalence of the amlodipine component of Boehringer Ingelheim Pharma GmbH \& Co. KGs 80 mg telmisartan/10 mg amlodipine fixed dose combination tablet to the corresponding mono-component amlodipine tablets, 10 mg (Pfizers Norvasc).

Detailed description:

Arms:
arm 1: Telmisartan/Amlodipine medium fixed dose combination tablet once daily. arm 2: Amlodipine Monocomponent 10mg tablet once daily

Interventions: intervention 1: Telmisartan/Amlodipine Combination Tablet intervention 2: Amlodipine Monocomponent
Intervention descriptions: intervention 1: Combination Tablet intervention 2: Active Comparator

Protocol document: